Papers/PMID:20430500
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation2010The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
methylcob(III)alamin — decreases asymmetric dimethylarginine (ADMA) concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The percentage of decrease in ADMA levels was greater in the methylcobalamin than folate group (25.4% +/- 10.2% vs 13.2% +/- 11.2%; P < 0.001).”
Quoted verbatim from Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.. - Study
- RCT
- Duration
- 3 weeks
- Dose
- 500 mcg intravenous methylcobalamin after each hemodialysis treatment, 3 times weekly, plus folate 15 mg/d
- Population
- Maintenance hemodialysis patients; oral folate 15 mg/d given to both arms as background, methylcobalamin added in one arm; 3 weeks, open-label
Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.2010PMID:20430500Permalink